NCT00001254 2026-01-08
Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome
National Institutes of Health Clinical Center (CC)
Completed
Clinical Trials
12 trialsNCT00454363 2020-04-03
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00001191 2017-07-02
The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001228 2017-07-02
Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001241 2017-07-02
Treatment of Zollinger-Ellison Syndrome
National Institutes of Health Clinical Center (CC)
Completed
NCT02153398 2017-01-19
A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
AstraZeneca
Phase 3 Completed
NCT00869050 2016-07-25
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
Phase 2 Completed
NCT01204476 2016-07-15
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00204373 2012-10-30
Treatment of Zollinger-Ellison Syndrome With Prevacid
University of Alabama at Birmingham
Phase 4 Completed
NCT00942175 2012-02-03
A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.
Takeda
Phase 1 Completed
NCT00079833 2010-11-19
Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome
AstraZeneca
Phase 3 Completed
NCT00001165 2008-03-04
Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed